OPTIKIRA, LLC
Small-molecule IRE1α inhibitors (OPK-KIRAs) for retinitis pigmentosa
- Sector
- Biotech
- Headquarters
- CLEVELAND, OH
- Founded
- 2014
- Latest Form D
- $1.1M, Jun 2018
- Total capital
- $3.3M
- Federal grants
- $2M
- 5 awards · 2015–2020
- Rank in peer group#53 of 326
- Private capital raised
- $1.4M
- 2 Form D · last Jun 2018
- 101 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 11 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Targeting the Unfolded Protein Response to Treat Retinitis Pigmentosa$775K
- Federal grantHealth and Human S · Phase II · Targeting the Unfolded Protein Response to Treat Retinitis Pigmentosa$795K
- Private capital raisedForm D · SEC · 2nd filing$1.1M
- Federal grantHealth and Human S · Phase I · IRE1 alpha inhibitors for Retinal Degenerative Diseases$73K
- Federal grantHealth and Human S · Phase I · IRE1 alpha inhibitors for Retinal Degenerative Diseases$122K
- Federal grantHealth and Human S · Phase I · IRE1 alpha inhibitors for type 2 diabetes$200K
- Private capital raisedForm D · SEC · 1st filing$250K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#53 · top 16%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Bradley BackesResearcherDirectorLinked by $395K in grants as PI
- Baiju ShahDirectorNamed in SEC Form D filings
- Dustin MalyDirectorNamed in SEC Form D filings
- Feroz PapaDirectorNamed in SEC Form D filings
- Mark ChinDirectorNamed in SEC Form D filings
- Scott OakesDirectorNamed in SEC Form D filings
Show all 7 people
- Theodore TorphyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 11- PendingPyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using SameUSPTOApplication 18020042
- PendingImidazolopyridine Compounds For IRE1 InhibitionUSPTOApplication 17433273
- PendingPyrazolopyridine Compounds For IRE1 InhibitionUSPTOApplication 17432842
Show all 11 patent records
- Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using SameOct 19, 2023 · Application 18020042Pending
- Imidazolopyridine Compounds For IRE1 InhibitionJun 23, 2022 · Application 17433273Pending
- Pyrazolopyridine Compounds For IRE1 InhibitionMay 19, 2022 · Application 17432842Pending
- Pyrazolopyridine Compounds And Methods Of Inhibiting IRE1 Using SameApplication PCTUS2021044917Pending
- Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using SameApplication 63062465Pending
- Pyrazolopyridine Compounds For IRE1 InhibitionApplication PCTUS2020020162Pending
- Imidazolopyrazine Compounds For IRE1 InhibitionApplication PCTUS2020020157Pending
- Imidazolopyridine Compounds For IRE1 InhibitionApplication 62813966Pending
- Pyrazolopyridine Compounds For IRE1 InhibitionApplication 62813975Pending
- Pyrazolopyridine Compounds For IRE1 InhibitionApplication 62811237Pending
- Imidazolopyridine Compounds For IRE1 InhibitionApplication 62811243Pending
Related companies, and why
- SHIFA BIOMEDICAL CORPORATIONSimilar federal contract value in Biotech · null in contracts
- MDI THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- NOVILYTIC, LLCSimilar federal contract value in Biotech · null in contracts
- AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- 7 Hills Pharma LLCSimilar federal contract value in Biotech · null in contracts
- AyuVis Research, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .